REGULATORY
Japan Doles Out Orphan Tags for Nihon Servier’s Vorasidenib, 11 More APIs
Japan’s Ministry of Health, Labor and Welfare (MHLW) on December 25 designated 12 APIs as orphan drugs including Nihon Servier’s recently filed glioma treatment vorasidenib as well as other medicines by Bristol Myers Squibb and Boehringer Ingelheim. Vorasidenib was granted…
To read the full story
REGULATORY
- LDP Panel Finalizes Honebuto Proposal on Preventive Care, Adds Obesity Focus
June 5, 2026
- Ex-GSK Japan Head Calls for End to "Obsolete" 14-Day Prescription Limit
June 5, 2026
- Trazenta Generic Outlook Remains Clouded as Court Upholds Treatment-Method Patents
June 4, 2026
- LDP Generic Caucus Wants Swift Disclosure of Company Indicator Ratings
June 4, 2026
- LDP Social Security Panel Pushes Greater Reward for Innovation: Honebuto Proposal
June 3, 2026
In the complex landscape of the Japanese pharmaceutical market, the “status quo” is often the safest harbor. But for leaders like Kennet Brysting, former president of Gilead Japan, the status quo is the most dangerous place to stay.Innovation in Japan…





